Affymax Receives Milestone Payment For Phase 3 Clinical Trials Of Hematide
Affymax said that the milestone was achieved with the initiation of Phase 3 clinical testing of Hematide to treat anemia in chronic renal failure patients in Japan. Hematide
The US Food and Drug Administration (FDA) has issued traditional approval to Novartis for Fabhalta (iptacopan), to slow the decline of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression.
Maybridge claimed that the Ro3 500 Fragment Library, selected from the original Maybridge “Rule-of-Three” (Ro3) compliant set, is designed to be a convenient, cost-effective entry point to fragment
The license comprises the patent application entitled ‘Identification of Ergothioneine Transporter and Therapeutic Uses Thereof.’ This transporter is present in human cells, especially red and white blood cells,